Phenobarbital Market Is Driven By Increasing Prevalence Of Epilepsy
Phenobarbital, also known as Luminal, is a prescription medication used to treat epilepsy and also as a secondary medication for anxiety and insomnia. It works by slowing down impulses in the brain that cause seizures. Phenobarbital comes in tablet, capsule, and injectable forms. The drug is very cost effective and its generic version is easily available, making it popular worldwide for treatment of epilepsy and seizures. However, its prolonged use may cause side effects such as sleepiness, irritability, or hyperactivity in some cases.
The Global Phenobarbital Market is estimated to be valued at US$ 1.83 Bn in 2024 and is expected to exhibit a CAGR of 7.2% over the forecast period 2024 to 2031.
The increasing prevalence of epilepsy is a key driver for the Phenobarbital Market Demand. As per the WHO, the lifetime prevalence of epilepsy is estimated to range from 4 to 10 cases per 1000 population across different regions. Around 50 million people worldwide have epilepsy currently. Additionally, head injuries, brain infections, brain tumors and genetic factors also contribute to epilepsy incidence. Phenobarbital remains the first line therapy for controlling seizures in newly diagnosed patients and is preferred due to its low cost and effectiveness. This growing disease prevalence worldwide will continue to drive the demand for anti-seizure drugs like phenobarbital.
Get more insights on Phenobarbital Market
Also read related article on m-RNA Synthesis Service Market
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian